PMID- 36697262
OWN - NLM
STAT- MEDLINE
DCOM- 20230321
LR  - 20230407
IS  - 1469-9001 (Electronic)
IS  - 1355-8382 (Print)
IS  - 1355-8382 (Linking)
VI  - 29
IP  - 4
DP  - 2023 Apr
TI  - Applications and future of aptamers that achieve rapid-onset anticoagulation.
PG  - 455-462
LID - 10.1261/rna.079503.122 [doi]
AB  - In this short Perspective, we discuss the history of, and recent progress toward, 
      the development of aptamers that can serve as rapid onset anticoagulants during 
      cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), and 
      catheter-based diagnostic and interventional procedures, several million of which 
      are performed each year worldwide. Aptamer anticoagulants provide potent and 
      antidote-controllable anticoagulation and have low immunogenicity. New methods of 
      aptamer isolation and engineering have not only improved the quality of aptamers, 
      but also accelerated their development. Unfortunately, no aptamer identified to 
      date can produce an anticoagulant effect as potent as that produced by 
      unfractionated heparin (UFH), the standard anticoagulant for CPB. We have 
      suggested several possible strategies to amplify the anticoagulant potency of 
      existing aptamer anticoagulants.
CI  - (c) 2023 Yu et al.; Published by Cold Spring Harbor Laboratory Press for the RNA 
      Society.
FAU - Yu, Haixiang
AU  - Yu H
AD  - Department of Surgery, Duke University Medical Center, Durham, North Carolina 
      27710, USA.
FAU - Frederiksen, James
AU  - Frederiksen J
AD  - Department of Surgery, Duke University Medical Center, Durham, North Carolina 
      27710, USA.
FAU - Sullenger, Bruce A
AU  - Sullenger BA
AD  - Department of Surgery, Duke University Medical Center, Durham, North Carolina 
      27710, USA bruce.sullenger@duke.edu.
AD  - Department of Pharmacology and Cancer Biology, Duke University Medical Center, 
      Durham, North Carolina 27710, USA.
LA  - eng
GR  - P01 HL139420/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230125
PL  - United States
TA  - RNA
JT  - RNA (New York, N.Y.)
JID - 9509184
RN  - 9005-49-6 (Heparin)
RN  - 0 (Aptamers, Nucleotide)
RN  - 0 (Anticoagulants)
RN  - 0 (Antidotes)
SB  - IM
MH  - *Heparin/pharmacology
MH  - *Aptamers, Nucleotide/pharmacology/therapeutic use
MH  - Blood Coagulation
MH  - Anticoagulants/pharmacology/therapeutic use
MH  - Antidotes/pharmacology
PMC - PMC10019365
EDAT- 2023/01/26 06:00
MHDA- 2023/03/22 06:00
PMCR- 2023/04/01
CRDT- 2023/01/25 21:42
PHST- 2023/01/26 06:00 [pubmed]
PHST- 2023/03/22 06:00 [medline]
PHST- 2023/01/25 21:42 [entrez]
PHST- 2023/04/01 00:00 [pmc-release]
AID - rna.079503.122 [pii]
AID - RA [pii]
AID - 10.1261/rna.079503.122 [doi]
PST - ppublish
SO  - RNA. 2023 Apr;29(4):455-462. doi: 10.1261/rna.079503.122. Epub 2023 Jan 25.